… et al., 1979) and 2-5 to 15 mg/kg (Laskin et al., 1982a) and multiple-dose studies from 2-5
to 15 mg/kg administered every 8 h (de Miranda et al., 1980; Whitley et al., 1982) have …

The metabolic disposition and pharmacokinetics of acyclovir have been studied as part of the
clinical evaluation of the drug in humans. Data from 10 studies have been summarized and…

… de Miranda & Gertrude B. Elion, … Lc 3 Ț 8 8 12 12 14 14 Sf SSS C 6 6 7 7 8 8 8 8 9 9
300 Т 4 4 6 6 7 7 7 7 7 8 C 3 3 3 3 3 3 3 3 3 34 | 3 Т 8 8 84 10 14 14 SSSS C 6 6 7 7 8 8 8 8 …

… P < 0.05 for paired comparisons from month 0 to month 18 for mean of the three … leptin, LH,
T, and cortisol significantly increased (P < 0.0001) from a baseline of 0.77 ± 0.01 … de Miranda …

… A detailed description of the assay, including validation data, will be published elsewhere
(Burnette TC, de Miranda P. Unpublished data). In brief, plasma samples were deproteinated …

Eighteen amino acid esters of the antiherpetic drug, acyclovir, were synthesized as potential
prodrugs for oral administration. The esters were examined for in vitro antiviral activity …

The basic pharmacokinetic and bioavailability information on zidovudine was obtained during
the initial phase I study. Following intravenous doses of 1.0 mg/kg every eight hours to 7.5 …

… WHITLEY R , BLUM M , BARTON N , and DE MIRANDA P . Pharmacokinetics of acyclovir
in humans following intravenous administration: a model for the development of parenteral …

… of DHPG were determined by HPLC according to the method of de Miranda and Page …
de Miranda P, Page DA. Disposition and pharmacokinetics of the antiviral drug BW B759U …

The effects of probenecid on the pharmacokinetics and renal clearance of acyclovir were
studied in humans. Acyclovir (5 mg/kg) was given as a 1-h infusion to three volunteers with …